The use of these agents, combined with standard-of-care therapies and the targeted inhibition of the PI3K-AKT pathway in patients with PTEN loss and ERG-TMPRSS fusions, may be a viable strategy to delay tumor progression and promote immunotherapeutic sensitivity in patients prior to progression to late stage PC. The gene discussed is AKT1; the disease is neoplasm.